English
 
My Account  

REGISTER & SECURE BENEFITS

  • View prices & discounts
  • Free gifts
  • Request & accept offers online
LOGIN NOW Not yet registered? Create your free account here!
Comparison

Puromycin (dihydrochloride) European Partner

Item no. HY-B1743A-5mg
Manufacturer MedChem Express
CASRN 58-58-2
Amount 5 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 500 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.89
Formula C22H31Cl2N7O5
Citations Acta Pharmacol Sin. 2023 Feb 20.
Adv Mater. 2022 Oct 20;e2206793.
Adv Sci (Weinh). 2024 Feb 21:e2308531.
Adv Sci (Weinh). 2024 Jun 26:e2404822.
Adv Sci (Weinh). 2024 Oct 18:e2407967.
Aging. 2020 Sep 14;12(17):17122-17136.
Aging. 2021 Jun 8;13(11):14892-14909.
Am J Cancer Res. 2023 May 15;13(5):1718-1743.
Am J Cancer Res. 2023 Sep 15;13(9):4222-4234.
Am J Transl Res. 2021 Apr 15;13(4):2331-2349.
Am J Transl Res. 2021 May 15;13(5):4360-4375.
Anal Biochem. 2021 Aug 29;114357.
Antioxid Redox Signal. 2022 Jun 16.
Antioxidants (Basel). 2023 Aug 18;12(8):1634.
Arch Biochem Biophys. 2023 May 19;109642.
Autophagy. 2021 Mar 25;1-19.
Autophagy. 2024 Jul 26:1-17.
Bioact Mater. 12 November 2021.
Biochem Biophys Res Commun. 1 January 2022, Pages 34-41.
Biochem Biophys Res Commun. 2021 Oct 5;580:48-55.
Biochem Biophys Res Commun. 6 August 2022.
Biochem Pharmacol. 2020 Apr;174:113776.
Biochem Pharmacol. 2024 Jul 10:116418.
Biochem Pharmacol. 2024 Jul 10:116422.
Biochem Pharmacol. 2024 May 9:225:116256.
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 20;1870(5):167195.
Biochim Biophys Acta Mol Basis Dis. 2024 Aug 5:167453.
Biochim Biophys Acta Mol Cell Res. 2024 Jun 3:119768.
Biodes Manuf. 03 March 2022.
Biodes Manuf. 2022 Apr 18.
Biol Res. 2024 May 17;57(1):30.
Biomed Pharmacother. 2020 Jan;121:109578.
bioRxiv. 2023 Mar 31.
bioRxiv. 2023 Oct 4.
bioRxiv. 2024 August 30.
bioRxiv. 2024 Mar 29.
bioRxiv. April 11, 2022.
BMC Cancer. 2018 Feb 13;18(1):182.
Bull Cancer. 2023 Feb 28;S0007-4551(23)00083-8.
Cancer Commun (Lond). 2022 Nov 9.
Cancer Immunol Res. 2023 Feb 22;CIR-22-0658.
Cancer Invest. 2021 Mar 8;1-34.
Cancer Lett. 2020 Nov 1;492:162-173.
Cancer Lett. 2021 Apr 29;S0304-3835(21)00180-4.
Cancer Lett. 2021 Jul 30;518:266-277.
Cancer Lett. 2024 Apr 9:591:216848.
Cancer Lett. 2024 Jan 25:216674.
Cancer Manag Res. 2021 Nov 30;13:8915-8928.
Cancer Med. 2019 Oct;8(13):5903-5915.
Cancer Res. 2023 Apr 16;CAN-22-3059.
Cancer Sci. 2024 Jun 26.
Cell Biol Toxicol. 2024 Aug 7;40(1):65.
Cell Commun Signal. 2022 Jun 15;20(1):87.
Cell Death Dis. 2020 Dec 2;11(12):1032.
Cell Death Dis. 2021 Oct 14;12(10):944.
Cell Death Dis. 2021 Sep 9;12(9):842.
Cell Death Dis. 2022 Apr 18;13(4):360.
Cell Death Dis. 2023 Feb 11;14(2):107.
Cell Death Dis. 2023 Nov 25;14(11):765.
Cell Death Dis. 2023 Oct 6;14(10):653.
Cell Death Dis. 2019 Nov 21;10(12):879. 
Cell Death Discov. 2021 Aug 30;7(1):226.
Cell Death Discov. 2021 May 1;7(1):89.
Cell Death Discov. 2022 Apr 23;8(1):222.
Cell Death Discov. 2022 Dec 16;8(1):493.
Cell Death Discov. 2022 Feb 22;8(1):77.
Cell Death Discov. 2022 Oct 28;8(1):432.
Cell Mol Biol (Noisy-le-grand). 2024 Jun 5;70(6):122-128.
Cell Mol Immunol. 2024 Jun;21(6):546-560.
Cell Rep. 2024 Aug 22;43(9):114662.
Cell Rep. 2024 Dec 13;43(12):115060.
Cell Rep. 2024 Feb 27;43(2):113739.
Cell Rep. 2024 Mar 23;43(4):114003.
Cell Signal. 2020, 109878.
Clin Epigenetics. 2022 Dec 2;14(1):164.
Clin Transl Oncol. 2021 Apr 7.
Clin Transl Oncol. 2022 Dec 13.
Commun Biol. 2022 Aug 30;5(1):887.
Comput Biol Med. 2024 Feb, 169, 107975.
Dig Liver Dis. 2022 Dec 29;S1590-8658(22)00827-1.
Dis Markers. 2022 Sep 23;2022:8402116.
DNA Cell Biol. 2022 Apr;41(4):447-455.
EMBO Rep. 2021 Jun 23;e52205.
Environ Toxicol. 2023 Mar 15.
Environ Toxicol. 2023 Oct 4.
Exp Cell Res. 2023 Apr 11;427(1):113598.
Exp Cell Res. 2023 Apr 24;113613.
Exp Cell Res. 2024 Apr 16;438(1):114038.
Exp Mol Med. 2022 Jul;54(7):890-905.
Exp Mol Pathol. 2021 Oct 5;104704.
F1000Research. 03 Aug 2022.
Front Oncol. 21 April 2021.
Gene. 2024 Aug 22:931:148855.
Genes (Basel). 2022, 13(10), 1760.
Heliyon. 2022 Dec 6;8(12):e12118.
Heliyon. 2023 Aug 9.
Heliyon. 2023 Nov 15.
Int Immunopharmacol. 2023 Jul 15;122:110616.
Int J Biol Macromol. 2023 Apr 17;124476.
Int J Mol Sci. 2023 Sep 23, 24(19), 14476.
Int J Oncol. 2023 Apr;62(4):45.
Int J Oncol. 2024 Apr;64(4):45.
J Appl Toxicol. 2023 Apr 14.
J Biol Chem. 2021 Feb 10;296:100413.
J Biol Chem. 2021 Jan 8;100276.
J Biol Chem. 2023 Mar;299(3):102961.
J Cancer. 2023 May 8; 14(8): 1309-1320.
J Cancer. 2024 Sep 9;15(17):5762-5772.
J Cell Mol Med. 2023 Mar 14.
J Ethnopharmacol. 2023 Apr 3;116446.
J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.
J Exp Clin Cancer Res. 2022 Mar 28;41(1):111.
J Exp Clin Cancer Res. 2023 Nov 6;42(1):294.
J Exp Clin Cancer Res. 2023 Oct 3;42(1):258.
J Hematol Oncol. 2021 Jul 10;14(1):109.
J Transl Med. 2024 Jun 20;22(1):584.
J Transl Med. 2024 May 21;22(1):485.
J Virol. 2024 Jun 28:e0083024.
Life Sci. 2022 Jan 19;293:120320.
Mbio. 2023 Oct 26:e0168823.
MedComm (2020). 2024 May 31;5(6):e576.
Mol Cancer. 2024 May 6;23(1):90.
Mol Cancer. 2019 Aug 22;18(1):127. 
Mol Carcinog. 2023 Jun 28.
Mol Cell Biochem. 2021 Jun;476(6):2503-2512.
Mol Cell. 2023 Nov 20:S1097-2765(23)00914-0.
Mol Cell. 2023 Nov 24:S1097-2765(23)00911-5.
Mol Cell. 2024 Aug 1:S1097-2765(24)00593-8.
Mol Pharm. 2024 Jun 6.
Molecules. 2023, 28(3), 1103.
Nat Commun. 2019 Dec 2;10(1):5492.
Nat Commun. 2022 Mar 10;13(1):1248.
Neuro Oncol. 2022 Jun 20;noac156.
NPJ Precis Oncol. 2024 Mar 1;8(1):58.
Nucleic Acids Res. 2024 Jan 2:gkad1243.
Oncogene. 2021 Nov 29.
Oncogene. 2023 Aug 18.
Oncol Lett. 2023 Dec 18.
Oncol Rep. 2021 Feb;45(2):523-534.
Oncol Rep. 2023 Aug;50(2):148.
Oncotargets Ther. 2020 Sep 30;13:9701-9719.
Peer J Prints. June 6, 2022.
Phytomedicine. 2023 Mar 15;114:154769.
Poult Sci. 2023 Jul 14, 102864.
Reprod Biomed Online. 2023 Jun 23.
Research Square Preprint. 2021 Aug.
Research Square Preprint. 2021 Nov.
Research Square Preprint. 2022 Jan.
Research Square Preprint. 2022 May.
Research Square Preprint. 2023 Apr 17.
Research Square Preprint. 2023 Nov 25.
Research Square Preprint. 2023 Sep 27.
Research Square Print. 2022 Aug.
Research Square Print. 2023 Mar 15.
Sci China Life Sci. 2024 Sep 6.
Sci Rep. 2022 Nov 5;12(1):18809.
Science. 2024 Feb 2;383(6682):eadh4859.
Signal Transduct Target Ther. 2022 Feb 28;7(1):54.
Signal Transduct Target Ther. 2024 Dec 18;9(1):352.
SSRN. 2021 Jun.
STAR Protoc. 2022 Apr 13;3(2):101296.
STAR Protoc. 2022 Nov 2;3(4):101808.
Stem Cell Res Ther. 2024 Dec 2;15(1):458.
Stem Cell Rev Rep. 2023 Jan 11.
Stem Cells Int. 2020 Aug 29;2020:8860185.
Thorac Cancer. 2024 May 8.
Transl Oncol. 2024 Apr 24:45:101958.
Transl Oncol. 2024 Jul 3:47:101950.
Vet Microbiol. 2023 Jun 28;284:109823.
Virus Res. 2023 Apr 15;328:199086.
Acta Pharmacol Sin. 2021 Jan;42(1):108-114.
Adv Funct Mater. 2019, 1808556.
Biochem Pharmacol. 2017 Mar 15;128:12-25.
Biol Direct. 2024 Nov 26;19(1):122.
bioRxiv. 2023 Jun 17.
bioRxiv. 2024 Sep 29:2024.09.26.615290.
Cancer Cell Int. 2019 Jul 24;19:192.
Cancer Immunol Res. 2023 May 2;CIR-22-0814.
Cell Signal. 2019 Mar 5;58:119-130.
Development. 2024 Sep 30:dev.202899.
Evid Based Complement Alternat Med. 2019 Mar 24;2019:1635837.
Hepatology. 2021 Apr;73(4):1327-1345.
Indian J Pharm Educ. 2024 Jun 21.
Int J Biol Sci. 2024 Oct 14;20(14):5548-5575.
Int J Oncol. 2020 Jul;57(1):161-170.
J Cell Mol Med. 2019 Feb;23(2):954-966.
J Exp Clin Cancer Res. 2016 Nov 7;35(1):173.
J Hepatocell Carcinoma. 2024 Sep 18:11:1763-1775.
J Transl Med. 2024 Nov 22;22(1):1052.
Mol Carcinog. 2024 Oct 10.
Onco Targets Ther. 2019 Jan 25;12:835-848. 
Oncogene. 2024 Oct 7.
Placenta. 2024 Oct 21:158:156-164.
PLoS One. 2017 Oct 10;12(10):e0185565.
R Soc Open Sci. 2018 Aug 29;5(8):172376.
Res Sq. 2024 Nov 07.
Theranostics. 2020 May 16;10(14):6483-6499.
Theranostics. 2021 Mar 5;11(10):5045-5060.
Toxicol Appl Pharmacol. 2019 Sep 1;378:114625.
Transl Res. 2023 Apr 28;S1931-5244(23)00072-5.
[1]Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.
[2]Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82.
[3]Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7.
Smiles OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O.[H]Cl.[H]Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias CL13900 (dihydrochloride)
Shipping condition Room temperature
Available
Manufacturer - Type
Natural Products
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Antibiotic; Bacterial; Parasite
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Description
Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
Manufacturer - Research Area
Infection; Cancer
Solubility
DMSO : 50 mg/mL (ultrasonic)|Ethanol : 5 mg/mL (ultrasonic; warming; heat to 60°C)|H2O : 50 mg/mL (ultrasonic; warming)|Methanol : 250 mg/mL (ultrasonic)
Manufacturer - Pathway
Anti-infection
Isoform
Aminoglycoside
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request product datasheet

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?

sales@hoelzel.de

 
Close

« Back

Contact

Hölzel Diagnostika Handels GmbH
Weinsbergstr 118a
50823 Cologne
Germany

T +49 221 126 02 66
F +49 221 126 02 67

info@hoelzel.de

About Hölzel
Service
Infodesk
Spendenaktion Datenschutzsiegel

Copyright 2025 Hölzel Diagnostika Handels GmbH

To top